DarioHealth Corp.

Listed Company

DRIOCIK 0001533998NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-41.71M

Total Assets

$110.08M

Equity

$67.92M

Shares Out

7.31M

Op. Cash Flow

$-25.94M

DRIO$6.82−51.30% · past yearDBEQ Basic

Daily closing prices

Business

DarioHealth Corp. is a vertically integrated digital health platform that combines FDA-cleared connected hardware devices, proprietary AI trained on billions of clinical data points, and behavioral coaching to address chronic condition management and mental health. The company offers bundled or individual solutions for cardiometabolic conditions (diabetes, hypertension, weight management), behavioral health, and musculoskeletal pain across direct-to-consumer and business-to-business channels. DarioHealth serves employers, health plans, and pharmaceutical companies globally with a subscription model priced on per-member or per-engaged-member-per-month bases, supported by over 100 peer-reviewed clinical studies demonstrating health outcomes and return on investment.

Summary from 10-K filed 2026-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	22	27	20	28	21
Total cost of revenues	10	14	14	18	17
Gross profit	13	13	6	10	4
Research and development	14	24	20	20	17
Sales and marketing	20	26	24	30	40
General and administrative	15	20	18	16	24
Total operating expenses	49	71	62	66	80
Operating loss	37	58	56	57	76
Interest expenses	3	—	—	—	—
Other financial expenses (income), net	2	−13	—	—	—
Total financial expenses (income), net	5	−13	3	5	235,000
Loss before taxes	42	45	59	62	77
Income taxes (benefit)	105,000	−2	64,000	4,000	32,000
Net loss	42	43	59	62	77
Deemed dividend (contribution)	20	−2	4	—	—
Net loss attributable to common shareholders	62	41	64	64	79
Basic net loss per share of common stock (in dollars per share)	10.12	12.27	1.93	2.54	4.07
Diluted net loss per share of common stock (in dollars per share)	10.12	12.27	1.93	2.54	4.07
Weighted average number of common stock used in computing basic and diluted net loss per share	4	2	28	24	17
Weighted average number of common stock used in computing diluted net loss per share (in shares)	4	2	28	24	17

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	22	28	37	49	36
Short-term bank deposits	4	697,000	—	—	—
Short-term restricted bank deposits	229,000	175,000	292,000	165,000	192,000
Trade receivables, net	2	5	3	6	1
Inventories	4	5	5	8	6
Other accounts receivable and prepaid expenses	2	2	2	2	2
Total current assets	35	41	47	66	46
Deposits	80,000	79,000	6,000	6,000	20,000
Operating lease right of use assets	717,000	1	967,000	1	287,000
Long-term assets	304,000	313,000	143,000	111,000	57,000
Property and equipment, net	549,000	709,000	899,000	788,000	702,000
Intangible assets, net	16	19	5	10	12
Goodwill	57	57	42	42	42
Total non-current assets	75	78	49	54	55
Total assets	110	119	96	119	101
Trade payables	3	3	1	2	5
Deferred revenues	714,000	2	997,000	1	1
Operating lease liabilities	430,000	504,000	111,000	293,000	266,000
Other accounts payable and accrued expenses	5	6	6	7	8
Current maturity of long-term loan	—	5	4	9	—
Total current liabilities	9	17	12	19	14
Operating lease liabilities	571,000	765,000	885,000	827,000	21,000
Long-term loan	31	23	25	18	0
Warrant liability	1	6	240,000	910,000	0
Other long-term liabilities	46,000	25,000	36,000	0	—
Total non-current liabilities	33	30	26	20	846,000
Common stock of $0.0001 par value - authorized: 400,000,000 shares; issued and outstanding: 6,905,948 and 1,919,420 shares on December 31, 2025 and December 31, 2024, respectively	4,000	4,000	3,000	3,000	2,000
Preferred stock of $0.0001 par value - authorized: 5,000,000 shares; issued and outstanding: 0 and 49,585 shares on December 31, 2025 and December 31, 2024, respectively	—	—	—	—	—
Additional paid-in capital	520	462	408	366	308
Accumulated deficit	−452	−390	−349	−286	−222
Total stockholders' equity	68	72	58	80	86
Total liabilities and stockholders' equity	110	119	96	119	101

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−42	−43	−59	−62	−77
Stock-based compensation	9	16	20	17	25
Change in operating lease right of use assets	421,000	907,000	239,000	−919,000	211,000
Amortization of acquired intangible assets	3	6	5	—	—
Depreciation and impairment	307,000	1	473,000	356,000	282,000
Change in fair value of warrant liability	−2	−17	−670,000	—	—
Non-cash financial expenses	3	516,000	—	—	—
Decrease in trade receivables, net	3	2	3	−5	−351,000
Increase in other accounts receivable, prepaid expense and long-term assets	−16,000	−80,000	−426,000	−3,000	−16,000
Decrease in inventories	437,000	308,000	3	−2	−2
Decrease in trade payables	−122,000	−496,000	−1	−3	1
Decrease in other accounts payable and accrued expenses	−780,000	−3	−256,000	−1	−865,000
Decrease in deferred revenues	−869,000	−156,000	−323,000	125,000	−157,000
Change in operating lease liabilities	−341,000	−1	−124,000	833,000	−245,000
Accrued interest on short term bank deposits	−14,000	—	—	—	—
Other	642,000	−580,000	−240,000	—	—
Net cash used in operating activities	−26	−39	−30	−48	−50
Purchase of property and equipment, net	−142,000	−138,000	−584,000	−442,000	−261,000
Investments in short-term bank deposits	−4	—	−5	—	—
Payments for business acquisitions, net of cash acquired	—	−9	—	—	—
Net cash used in investing activities	−4	−9	−547,000	−573,000	−8
Proceeds from issuance of common stock and prefunded warrants, net of issuance costs	17	—	—	—	—
Proceeds from issuance of preferred stock, net of issuance costs	7	39	15	—	—
Proceeds from borrowings on credit agreement, Net of issuance cost	32	—	30	24	—
Repayment of long-term loan	−32	—	−28	—	—
Net cash provided by financing activities	24	39	18	62	66
Increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents	−6	−9	−13	14	7
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash equivalents	9,000	−68,000	—	—	—
Cash paid during the period for interest on long-term loan	3	4	4	2	—
Right-of-use assets obtained in exchange for lease liabilities	73,000	428,000	136,000	1	—
Purchase of property and equipment on credit	5,000	—	—	—	—
Exercise of pre-funded warrants to common stock upon acquisition	3	2	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is DarioHealth Corp.'s CIK number?

DarioHealth Corp.'s SEC CIK number is 0001533998 (1533998). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find DarioHealth Corp.'s SEC filings?

All of DarioHealth Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →